Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits....
Saved in:
Main Authors: | Renliang Yi, Baoxin Chen, Peng Duan, Chanjiao Zheng, Huanyu Shen, Qun Liu, Chen Yuan, Weilin Ou, Zhiheng Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2016/4543861 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
by: Jennifer H. Gunter, et al.
Published: (2012-01-01) -
Calcium Activation of the Androgen Receptor in Prostate Cells
by: Zeina W. Sharawi, et al.
Published: (2023-01-01) -
Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
by: Manish Kohli, et al.
Published: (2012-01-01) -
The correlation between the expression of androgen receptor splice variant-7 (AR-V7) protein with the time of occurrence of castration-resistant prostate cancer and overall survival in prostate cancer in Indonesian population
by: Indrawarman Soerohardjo, et al.
Published: (2025-02-01) -
Androgen Receptor-Target Genes in African American Prostate Cancer Disparities
by: Bi-Dar Wang, et al.
Published: (2013-01-01)